Author:
Yates M,Malaiya R,Stack J,Galloway J B
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J et al. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford, England) 2017; 56 (6): 865–868.
2. Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae S-C et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2015; 74 (8): 1530–1536.
3. Humphreys JH, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons DP . The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis 2013; 72 (8): 1315–1320.
4. Johnson AE, Gordon C, Palmer RG, Bacon PA . The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995; 38 (4): 551–558.
5. Content.digital.nhs.uk. (2017). Find data - NHS Digital. [online] Available at:
http://content.digital.nhs.uk/searchcatalogue?productid=24706&q=+title%3a%22prescription+cost+analysis%22&sort=Relevance&size=10&page=1#top
(Accessed 1 June 2017).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献